Difference between revisions of "Brigatinib (Alunbrig)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714373 NCI Drug Dictionary]: An orally available inhibitor of receptor tyrosi...") |
m (PeterYang moved page Brigatinib (AP26113) to Brigatinib (Alunbrig): FDA approval) |
(No difference)
| |
Revision as of 03:21, 29 April 2017
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Dual ALK/EGFR inhibitor AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance.